# EMPagliflozin After Aortic Valve Replacement

Study · id `cardio:ct-nct06171802` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06171802](<https://clinicaltrials.gov/study/NCT06171802>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06171802

Browse, organ or system: Heart  
Browse, condition area: Valve and congenital heart disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 206 participants.

## Technical summary

Registry record NCT06171802. Randomized; quadruple masking; primary purpose treatment. Start 2024-02-14 (actual); primary completion 2026-05-08 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 206 participants (enrolled count; ClinicalTrials.gov record NCT06171802, source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)
- Started: 2024-02-14 (actual) (ClinicalTrials.gov record NCT06171802, source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)
- Primary completion: 2026-05-08 (actual) (ClinicalTrials.gov record NCT06171802, source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)
- Completion: 2026-05-18 (actual) (ClinicalTrials.gov record NCT06171802, source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)
- Countries: Denmark (ClinicalTrials.gov record NCT06171802, source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06171802-2026-05-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: EMPagliflozin After Aortic Valve Replacement
- Acronym: EMPAVR
- Condition: Aortic Valve Stenosis
- Intervention (Drug): Empagliflozin
- Intervention (Drug): Placebo
- Lead sponsor: Copenhagen University Hospital, Rigshospitalet
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Aortic stenosis (`cardio:aortic-stenosis`)
- Registry condition terms include this condition: Heart valve disease (`cardio:heart-valve-disease`)
- Registry intervention name matches this record: Empagliflozin (`cardio:empagliflozin`)
- Registry intervention is a member of this class by a sourced record link: SGLT2 inhibitors (drug class) (`cardio:sglt2-inhibitors`)
- Registry lists this organization as the lead sponsor: Copenhagen University Hospital, Rigshospitalet (`cardio:org-copenhagen-university-hospital-rigshospitalet`)

## Provenance

Content hash: d050e93b3e60ae9901e685d2fd30de24f82c3516758a2e6ffc49fd678e5497e6
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
